We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+56.41%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$281M
AUM Growth
+$70.9M
Cap. Flow
+$19.6M
Cap. Flow %
6.97%
Top 10 Hldgs %
63.76%
Holding
43
New
10
Increased
13
Reduced
5
Closed
13

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$8.77M
2
MIST icon
Milestone Pharmaceuticals
MIST
+$7.16M
3
ARWR icon
Arrowhead Research
ARWR
+$6.83M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$6.55M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$5.96M

Top Sells

Rank Stock Value
1
CASM
CAS Medical Systems, Inc.
CASM
+$12.8M
2
ASMB icon
Assembly Biosciences
ASMB
+$9.54M
3
DERM
Dermira, Inc.
DERM
+$8.63M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.79M
5
CBAY
Cymabay Therapeutics
CBAY
+$6.87M

Sector Composition

Rank Sector Weight
1 Healthcare 86.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.19M 0.78%
+50,000
New +$2.82M
ASMB icon
27
Assembly Biosciences
ASMB
$503M
$2.13M 0.76%
13,167
-50,208
-79% -$9.54M
DHR icon
28
Danaher
DHR
$139B
$1.64M 0.58%
+12,972
New +$1.54M
CMRX
29
DELISTED
Chimerix, Inc.
CMRX
$1.21M 0.43%
+280,000
New +$861K
CEMI
30
DELISTED
Chembio diagnostics, Inc.
CEMI
$254K 0.09%
41,667
– –
ALEC icon
31
Alector
ALEC
$168M
– –
-200,000
Closed -$3.74M
ALLK
32
DELISTED
Allakos
ALLK
– –
-13,500
Closed -$547K
AMRN
33
Amarin Corp
AMRN
$297M
– –
-4,375
Closed -$1.82M
BCRX icon
34
BioCryst Pharmaceuticals
BCRX
$2.24B
– –
-25,000
Closed -$204K
ENTA icon
35
Enanta Pharmaceuticals
ENTA
$377M
– –
-61,000
Closed -$5.83M
GOSS icon
36
Gossamer Bio
GOSS
$84.9M
– –
-60,000
Closed -$1.3M
NVAX icon
37
PUT
Novavax
NVAX
$1.22B
– –
-12,500
Closed -$138K
STRO icon
38
Sutro Biopharma
STRO
$416M
– –
-4,550
Closed -$518K
CBAY
39
DELISTED
Cymabay Therapeutics
CBAY
– –
-517,500
Closed -$6.87M
ACER
40
DELISTED
Acer Therapeutics Inc
ACER
– –
-147,000
Closed -$3.57M
QTNT
41
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-7,000
Closed -$2.52M
DERM
42
DELISTED
Dermira, Inc.
DERM
– –
-636,500
Closed -$8.63M
CASM
43
DELISTED
CAS Medical Systems, Inc.
CASM
– –
-5,263,508
Closed -$12.8M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Acuta Capital Partners held 43 positions worth $281M, up 34% from $210M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Acuta Capital Partners deployed $19.6M of net new capital in Q2 2019, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Axsome Therapeutics: 437,500 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Assembly Biosciences, an estimated $9.54M trimmed.

  • Acuta Capital Partners's largest Q2 2019 buy was Axsome Therapeutics: 437,500 shares worth $11.3M.
  • Acuta Capital Partners added most to Arrowhead Research in Q2 2019, an estimated $6.83M increase.
  • Acuta Capital Partners's biggest Q2 2019 reduction was Assembly Biosciences, cutting an estimated $9.54M.
  • Acuta Capital Partners fully exited CAS Medical Systems, Inc. in Q2 2019, selling an estimated $12.8M.
  • Acuta Capital Partners's ten largest holdings make up 64% of its $281M portfolio in Q2 2019.
  • Acuta Capital Partners opened 10 new positions and closed 13 in Q2 2019.
  • Acuta Capital Partners's portfolio value rose 34% quarter-over-quarter to $281M.

Based on Acuta Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.